BioXcel Therapeutics (BTAI) Gross Profit (2022 - 2026)

BioXcel Therapeutics has reported Gross Profit for 5 years, with the latest figure at $160000.0 in Q2 2026.

• On a quarterly basis, Gross Profit rose 1130.77% year-over-year to $160000.0 in Q2 2026; TTM through Jun 2026 was $394000.0, a 131.39% increase from a year earlier, with the FY2025 full-year figure at $478000.0, up 288.62% from the prior year.
• Gross Profit was $160000.0 for Q2 2026 at BioXcel Therapeutics, up from -$77000.0 in the prior quarter.
• The five-year high for Gross Profit was $1.0 million in Q2 2024, with the low at -$956000.0 in Q3 2024.
• Average Gross Profit over 5 years is $72312.5, with a median of $140000.0 recorded in 2022.
• The sharpest annual moves came in 2024 and 2026: Gross Profit plunged 459.06% in 2024, then surged 1130.77% in 2026.
• Over 5 years, Gross Profit stood at $229000.0 in 2022, then tumbled by 247.6% to -$338000.0 in 2023, then sank by 37.87% to -$466000.0 in 2024, then surged by 148.07% to $224000.0 in 2025, then slipped by 28.57% to $160000.0 in 2026.
• The last three Gross Profit figures came in at $160000.0 (Q2 2026), -$77000.0 (Q1 2026), and $224000.0 (Q4 2025), per Business Quant data.